Posted by Michael Wonder on 13 Jul 2025
Zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma
10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults with relapsed or refractory mantle cell lymphoma after just one line of treatment.
Zanubrutinib can be used as an option for the treatment of adults with relapsed or refractory mantle cell lymphoma who have had just 1 line of treatment only if BeiGene provides it according to the commercial arrangement.
